Hims & Hers class action overview:
- Who: Two consumers filed a class action lawsuit against Hims & Hers Health Inc. and Hims Inc.
- Why: The plaintiffs claim Hims & Hers falsely advertises its compounded semaglutide products as being the same as Ozempic and Wegovy.
- Where: The class action lawsuit was filed in Illinois federal court.
A new class action lawsuit alleges Hims & Hers falsely advertises its compounded GLP-1 semaglutide products as being the same as the weight loss and diabetes drugs Ozempic and Wegovy.
Plaintiffs Andrew Donoho and Gloria Ferguson’s class action lawsuit claims the compounded semaglutide products sold by Hims & Hers contain a different active ingredient than the semaglutide found in Ozempic and Wegovy, using a different manufacturing process.
This process can result in health consequences, such as immunogenicity, which can cause a consumer’s immune system to trigger a response, the Hims & Hers class action alleges.
“Consumers do not want to inject substances into their body without reasonable assurances that the substance is safe and effective,” the lawsuit states.
Donoho and Ferguson want to represent a nationwide class and Illinois subclass of consumers who purchased Hims & Hers’ compounded GLP-1 injectable semaglutide product.
Hims & Hers GLP-1 injectable not evaluated by FDA, class action claims
Hims & Hers’ compounded semaglutide products have not been meaningfully tested for safety or effectiveness or evaluated by the U.S. Food and Drug Administration, Donoho and Ferguson argue.
“If Hims & Hers told consumers the truth — that its product is different than Ozempic and Wegovy, uses a different active ingredient with peptides in addition to semaglutide, is manufactured with little to no oversight, has never been meaningfully tested for safety or effectiveness and has never been evaluated by FDA — then consumers would either not buy the product or they would pay far less for it,” the Hims & Hers class action lawsuit says.
The FDA issued a warning letter to Hims & Hers in September 2025 over claims the company made about its compounded GLP-1 semaglutide product.
The plaintiffs claim Hims & Hers is guilty of violating the Illinois Consumer Fraud and Deceptive Trade Practices Act and similar state statutes and of unjust enrichment.
Meanwhile, the manufacturer of Ozempic, Novo Nordisk, is facing various claims it failed to warn consumers about serious health issues, including gastroparesis, regarding its drug.
Did you purchase GLP-1 products from Hims & Hers? Let us know in the comments.
The plaintiffs are represented by John D. Polivick of Polivick Law Firm.
The Hims & Hers class action lawsuit is Donoho, et al. v. Hims & Hers Health Inc., et al., Case No. 1:26-cv-01954, in the U.S. District Court for the Northern District of Illinois.
Don’t Miss Out!
Check out our list of Class Action Lawsuits and Class Action Settlements you may qualify to join!
Read About More Class Action Lawsuits & Class Action Settlements:
- Disney agrees to $50M class action settlement over streaming TV price claims
- BMW recalls more than 58K vehicles due to faulty air conditioning system
- Figure Lending data breach class action alleges company failed to protect sensitive data
- Walmart $100M class action settlement resolves FTC driver pay lawsuit
